As of 2026-09-26, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -0.79 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.60 USD, the upside of Rocket Pharmaceuticals Inc is -130.44%.
Based on its market price of 2.60 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 130.44%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.79 - -0.79 | -0.79 | -130.44% |
| P/E | (3.02) - (4.04) | (3.40) | -231.0% |
| DDM - Stable | (2.98) - (37.12) | (20.05) | -872.7% |
| DDM - Multi | (0.64) - (5.96) | (1.14) | -144.0% |
| Market Cap (mil) | 283.35 |
| Beta | 2.29 |
| Outstanding shares (mil) | 109.19 |
| Enterprise Value (mil) | 80.11 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.05% |
| Cost of Debt | 5.00% |
| WACC | 5.93% |